Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 200-207

  Robaina, Marcela C ^a   Mazzoccoli, Luciano ^a   Arruda, Viviane Oliveira ^a   Reis, Flaviana Ruade de Souza ^a   Apa, Alexandre Gustavo ^a   de Rezende, Lidia Maria Magalhães ^a   Klumb, Claudete Esteves ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Burkitt lymphoma; Decitabine; DNMT1; DNMT3A; DNMT3B; MiR 29 family

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; UNCLASSIFIED DRUG; 5-AZA-2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE; AZACITIDINE; CYTIDINE TRIPHOSPHATE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; MESSENGER RNA; MICRORNA; MIRN29 MICRORNA, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; BURKITT LYMPHOMA CELL LINE; CANCER STAGING; CARCINOGENESIS; CELL GROWTH; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA METHYLATION; DNMT1 GENE; DNMT3A GENE; DNMT3B GENE; DNMT3B7 GENE; EPSTEIN BARR VIRUS; FEMALE; GENE OVEREXPRESSION; GENETIC DEREGULATION; GENETIC REGULATION; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; P16 INK4A GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VIRUS DETECTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PRESCHOOL CHILD; PROMOTER REGION; TUMOR CELL LINE;

ADOLESCENT; AZACITIDINE; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTIDINE TRIPHOSPHATE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84924662962     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.03.006     Document Type: Article

References (70)

1. Alkebsi L., et al. DNMT3B7 expression related to MENT expression and its promoter methylation in human lymphomas. Leuk. Res. 2013, 37:1662-1667.
2. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9:2395-2402.
3. Bestor T.H. Unanswered questions about the role of promoter methylation in carcinogenesis. Ann. N. Y. Acad. Sci. 2003, 983:22-27.
4. Broske A.M., et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 2009, 41:1207-1215.
5. Bueno M.J., et al. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood 2011, 117:6255-6266.
6. Bui T.V., Mendell J.T. Myc: maestro of microRNAs. Genes Cancer 2010, 1:568-575.
7. Chang T.C., et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
8. Choi M.S., et al. Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum. Pathol. 2003, 34:11-17.
9. Couronne L., et al. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 2012, 366:95-96.
10. Cummins J.M., et al. The colorectal microRNAome. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3687-3692.
11. Dalla-Favera R., et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7824-7827.
12. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
13. Dave S.S., et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 2006, 354:2431-2442.
14. De S., et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013, 9:e1003137.
15. Denis H., et al. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011, 12:647-656.
16. Di Lisio L., et al. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012, 120:1782-1790.
17. Fabbri M., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15805-15810.
18. Fernandez A.F., et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 2012, 22:407-419.
19. Garzon R., Croce C.M. MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol. 2008, 15:352-358.
20. Garzon R., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
21. Garzon R., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
22. Girault I., et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 2003, 9:4415-4422.
23. Hecht J.L., Aster J.C. Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. 2000, 18:3707-3721.
24. Hermann A., et al. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J. Biol. Chem. 2004, 279:48350-48359.
25. Jaffe E.S., et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008, 112:4384-4399.
26. Jardin F., Figeac M. MicroRNAs in lymphoma, from diagnosis to targeted therapy. Curr. Opin. Oncol. 2013, 25:480-486.
27. Ji H., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467:338-342.
28. Jones P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13:484-492.
29. Jurkowska R.Z., et al. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
30. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
31. Kim H., et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006, 107:1042-1049.
32. Kinney S.R., Pradhan S. Regulation of expression and activity of DNA (cytosine-5) methyltransferases in mammalian cells. Prog. Mol. Biol. Transl. Sci. 2011, 101:311-333.
33. Klumb C.E., et al. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur. J. Haematol. 2003, 71:81-90.
34. Klumb C.E., et al. Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil. Int. J. Cancer 2004, 108:66-70.
35. Klumb C.E., et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J. Pediatr. Hematol. Oncol. 2004, 26:462-468.
36. Lai A.Y., et al. DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Res. 2013, 23:2030-2041.
37. Ley T.J., et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363:2424-2433.
38. Li K.K., et al. DNA methyltransferases in hematologic malignancies. Semin. Hematol. 2013, 50:48-60.
39. Lin C.Y., et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
40. Lindstrom M.S., Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin. Cancer Biol. 2002, 12:381-387.
41. Mizuno S., et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179.
42. Mutze K., et al. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur. J. Cancer 2011, 47:1817-1825.
43. Nguyen T., et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011, 6:388-394.
44. Nosho K., et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin. Cancer Res. 2009, 15:3663-3671.
45. Okano M., et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
46. Ostler K.R., et al. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 2007, 26:5553-5563.
47. Pasqualucci L., et al. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 2008, 40:108-112.
48. Peng D.F., et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 2005, 96:403-408.
49. Peters S.L., et al. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol. Cell. Biol. 2013, 33:4321-4333.
50. Peters S.L., et al. Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis. Leukemia 2014, 28:1138-1142.
51. Psathas J.N., Thomas-Tikhonenko A. MYC and the art of microRNA maintenance. Cold Spring Harb. Perspect. Med. 2014, 4(8). pii: a014175.
52. Robaina M.C., et al. Quantitative analysis of CDKN2A methylation, mRNA, and p16 protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications. Leuk. Res. 2014.
53. Robertson K.D., et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27:2291-2298.
54. Robertus J.L., et al. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br. J. Haematol. 2010, 149:896-899.
55. Roll J.D., et al. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer 2008, 7:15.
56. Sander S., et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22:167-179.
57. Schmitz R., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
58. Shaffer A.L., et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000, 13:199-212.
59. Shah M.Y., et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res. 2010, 70:5840-5850.
60. Shaknovich R., et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood 2011, 118:3559-3569.
61. Song J., et al. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 2012, 335:709-712.
62. Subramaniam D., et al. DNA methyltransferases: a novel target for prevention and therapy. Front. Oncol. 2014, 4:80.
63. Suzuki M., et al. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 2004, 64:3137-3143.
64. Tagawa H., et al. Role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci. 2013, 104:801-809.
65. Taub R., et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7837-7841.
66. Tsai C.T., et al. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget 2014, 5:211-223.
67. Vasilatou D., et al. The role of microRNAs in normal and malignant hematopoiesis. Eur. J. Haematol. 2010, 84:1-16.
68. Wang Y., et al. The role of miRNA-29 family in cancer. Eur. J. Cell Biol. 2013, 92:123-128.
69. Xiong Y., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
70. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.